Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Medivation/Astellas Will Be Ready For Xtandi To Enter Pre-Chemo Prostate Cancer Setting

Mar 18 2014

• By Lisa LaMotta

Related Content

PREVAIL Impresses, But Prostate Docs Wary Of Declaring Victory For <em>Xtandi</em> Over <em>Zytiga</em>

Feb 03 2014

Accelerated Evolution Of Prostate Cancer Therapy Shaped <em>Xtandi</em> Review

Dec 18 2012

Can <em>Zytiga </em>Prevail In Pre-Chemo Prostate Cancer Without Proof Of Survival Benefit?

Dec 17 2012

Medivation/Astellas’ <em>Xtandi</em> A Tough Rival For J&J’s <em>Zytiga</em>

Sep 10 2012

Medivation/Astellas Confident <em>Xtandi</em> Data Will PREVAIL With Urologists

Oct 28 2013

Related Companies

Medivation, Inc.

Astellas Pharma, Inc.

Johnson & Johnson

Additional Topics

United States Regulation Approvals BioPharmaceutical

More from United States

More from North America

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window